QINA for Cancer patients

Background:

Cancer not only affects the individual, but has a distressing
effect on the surrounding family and friends who feel completely
helpless to act. As a coping mechanism, the psychology of
the cancer patient goes through a series of mind altering
processes that helps them prepare for the possible consequences
of this debilitating disease. The scope of the Qina clinical
trials focused on two areas.
(1.) To ensure the quality of
life
of the cancer patient and
(2.) To increase the duration
of life.

What
can Qina offer you as a Cancer patient:

We have already
discussed the effects on the key cell of the immune system
the Macrophage. Macrophages are believed to help cancer cells proliferate. They
are attracted to oxygen-starved (hypoxia) tumour cells
and promote chronic inflammation. Inflammatory compounds
such as Tumor necrosis factor (TNF) released by the macrophage
activates the gene switch nuclear factor-kappa B. NF-kB then enters the nucleus of a tumour cell and turns on
production of proteins that stop apoptosis and promote
cell proliferation
and inflammation. It is known through clinical studies
that Qina possesses anti inflammatory properties by the
activation and modulation of the Macrophage. The resulting
conclusion is that Qina provides, amongst other beneficial
factors, an improved Quality of Life.

The standard medical
protocol in treating cancer includes some of the most toxic
therapies known to man. The collateral
side effects can be as debilitating as the disease itself.
Qina offers both the patient and the surrounding family and
friends the power to provide a solution to "quality
of life" as this aspect is generally ignored by physicians.

Qina does not profess to be a cure for cancer, however the following statements
have been proven in large clinical trials.
Qina provides
a
regression of the symptoms, which include a lessening of pain, improved appetite,
weight gained, increased cognitive function and an overall feeling of wellness returns.
There is also evidence of the regression of the lesion itself,
thus making the disease's prognosis, look considerably better.
The largest difficulty
of antineoplastic chemotherapy, is drug resistance.
The performance of Qina on these patients promoted an adhesion
to the treatment for the improvement of life quality, with
a decrease in side effects and the absence of myelosuppression provoked by the
chemotherapy
drugs, allowing adherence to the treatment and for the continuity
of antineoplastic effects, to be maintained.

What does
this mean ?

Qina's consistent
performance demonstrated constant weight
gain, and avoidance of loss of corporal mass, which
are characteristics of the disease and the aggressive
therapy, a return of full cognitive
function where the accomplishment of
physical activities such as walking, leisure activities
and even the return, even if partial, to productive activities
were made possible.

Patients treated with Qina, in conjunction with conventional
therapies presented a decrease in pain complaints, improvement
in appetite and cognitive function were noticed almost
immediately after the start of the treatment, with continuous
constant
improvement over time. There is a noticeable reduction
in nausea and vomiting and a general feeling of well being.
The possibility of physical activities were a result in
the improvement of life quality and it
provided
an improvement of observed self-esteem during the treatment.

Conclusion

The performance progression shows with clarity that a
medication without toxicity and/or collateral effects,
acting on the body defences, becomes indispensable to the modern
therapeutic arsenal. In most of the patients, there
was
a significant decrease of tumour volumes, after the therapy
with Qina. This fact made it possible to discuss the
option of re-instituting invasive treatments or, surgery or even
restarting the cycle of chemotherapy, which had been
stopped.

Another verified fact is the high adhesion index to the
treatment with Qina where the attending patients went in
search of the medication so that they could remain on the
treatment after the study. Even in those where there was
partial or total tumor mass resolution, the interest of
carrying on taking the medication was unanimous.